Compare CFND & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CFND | MDXH |
|---|---|---|
| Founded | N/A | 2003 |
| Country | | Belgium |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 21.1M |
| IPO Year | 2025 | 2021 |
| Metric | CFND | MDXH |
|---|---|---|
| Price | $3.01 | $0.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 23.0K | ★ 325.5K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.85 | $0.40 |
| 52 Week High | $9.67 | $5.33 |
| Indicator | CFND | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 36.47 | 34.72 |
| Support Level | $2.85 | N/A |
| Resistance Level | $3.53 | $3.79 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 13.13 | 28.30 |
C1 Fund Inc is a non-diversified, closed-end management investment company. The Adviser provides day-to-day investment management services to the Company, which is classified as non-diversified under the Investment Company Act. The Company's investment objective is to maximize its portfolio's total return by principally investing in privately held equity and equity-linked securities of digital asset services and technology companies. Its investments in equity securities include common and preferred shares, securities convertible into common shares, warrants and rights to subscribe to or purchase common shares, and common shares carrying a warrant or right.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.